Schmid continued, “ We know it is crucial to learn about other ways and therapies that can be more inclusive for heart failure. “Consistent with our recent priorities, we will grow by accelerating the pace at which new therapeutics can reach patients and solutions to address growing healthcare unmet needs.
J&J $1.7B V-Wave Buy : V-Wave’s Breakthrough Implant Technology
With the acquisition of V-Wave, J&J is set to further penetrate into cardiologist as well heart failure specialist relationships since it relies on one-of-a-kind cardiovascular implants. One such product is the Ventura interatrial shunt implant designed to treat congestive heart failure, awarded Breakthrough Device Designation by FDA in 2019.
J&J picked out V-Wave’s device claiming it could be the world’s first of its kind on market, making a significant disruptor for heart failure treatment. “V-Wave’s breakthrough technology has the potential to help tens of thousands of patients who suffer from HF symptoms despite already being on oral medications while reducing heart failure-related hospitalizations and associated healthcare costs,” said Dr. Neal Eigler, CEO of V-Wave in a statement announcing the deal with J&J. “We are confident that Johnson & Johnson MedTech is well positioned to ensure V‑Wave’s next generation solutions benefit these many millions of patients experiencing this life-threatening condition as quickly and efficiently as possible.”
J&J $1.7B V-Wave Buy : Legal Teams Behind the Deal
V-Wave was advised by Kirkland & Ellis LLP, with a team led by corporate partners Lauren Colasacco, Daniel Wolf and Jimin He as well as tax partner Sara Zablotney. Johnson & Johnson did not disclose legal representation and representatives of the company could not immediately be reached for comment.
